{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:49:36Z","timestamp":1793148576253,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ncl.2024.12.011","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:36:45Z","timestamp":1738741005000},"page":"365-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Precision Medicine in Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Gadi","family":"Maayan Eshed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy N.","family":"Alcalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ncl.2024.12.011_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrg.2016.86","article-title":"Towards precision medicine","volume":"17","author":"Ashley","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ncl.2024.12.011_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-statistics-030718-105251","article-title":"Precision medicine","volume":"6","author":"Kosorok","year":"2019","journal-title":"Annu Rev Stat Appl"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.011_bib3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.011_bib4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.011_bib5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.011_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s13311-020-00920-8","article-title":"Emerging targeted therapeutics for genetic subtypes of parkinsonism","volume":"17","author":"Schneider","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.011_bib8","first-page":"899","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.ncl.2024.12.011_bib9","article-title":"GBA1-and LRRK2-directed treatments: the way forward","volume":"122","author":"Maayan","year":"2024","journal-title":"Parkinsonism Relat Disorders"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.011_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167932","article-title":"From lysosomal storage disorders to Parkinson's disease - challenges and opportunities","volume":"435","author":"M\u00e4chtel","year":"2023","journal-title":"J\u00a0Mol Biol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.011_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00441-017-2704-y","article-title":"Molecular mechanisms of \u03b1-synuclein and GBA1 in Parkinson's disease","volume":"373","author":"Stojkovska","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.011_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"10.1016\/j.ncl.2024.12.011_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson's disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2024.12.011_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","article-title":"Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies","volume":"10","author":"Chiasserini","year":"2015","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.011_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.011_bib16","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/acn3.51164","article-title":"Longitudinal measurements of glucocerebrosidase activity in Parkinson's patients","volume":"7","author":"Alcalay","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.011_bib17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid \u03b2-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter \u03b1-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.011_bib18","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/mds.26278","article-title":"No evidence for substrate accumulation in Parkinson brains with GBA mutations","volume":"30","author":"Gegg","year":"2015","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.011_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcmd.2012.11.011","article-title":"Phenotype in patients with Gaucher disease and Parkinson disease","volume":"50","author":"Chetrit","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.011_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.011_bib21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","article-title":"Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Giladi","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.011_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mds.28846","article-title":"Plasma glucosylsphingosine in GBA1 mutation carriers with and without Parkinson's disease","volume":"37","author":"Surface","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.011_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108419","article-title":"Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues","volume":"246","author":"Menozzi","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.011_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","article-title":"LRRK2 and idiopathic Parkinson's disease","volume":"45","author":"Rocha","year":"2022","journal-title":"Trends Neurosci"},{"issue":"451","key":"10.1016\/j.ncl.2024.12.011_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson's disease","volume":"10","author":"Di Maio","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.011_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41531-023-00482-4","article-title":"Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson's disease","volume":"9","author":"Gomes","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.011_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11910-021-01100-7","article-title":"The role of genetic testing for Parkinson's disease","volume":"21","author":"Cook","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"35","key":"10.1016\/j.ncl.2024.12.011_bib37","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J\u00a0Biol Chem"},{"issue":"Pt 5","key":"10.1016\/j.ncl.2024.12.011_bib38","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.011_bib39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.stemcr.2017.01.011","article-title":"A\u00a0human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers","volume":"8","author":"Yang","year":"2017","journal-title":"Stem Cell Rep"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.011_bib40","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","article-title":"Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons","volume":"8","author":"Magalhaes","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.011_bib41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.011_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/syn.21967","article-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","volume":"71","author":"Migdalska-Richards","year":"2017","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.011_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2012.04.018","article-title":"Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant \u03b2-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant","volume":"106","author":"Babajani","year":"2012","journal-title":"Mol Genet Metabol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.011_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.011_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2013","journal-title":"Brain Dev"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.011_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.011_bib52","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/mds.29346","article-title":"A\u00a0phase 1B trial in GBA1-associated Parkinson's disease of BIA-28-6156, a glucocerebrosidase activator","volume":"38","author":"den Heijer","year":"2023","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.011_bib54","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/mds.29190","article-title":"Putaminal recombinant glucocerebrosidase delivery with magnetic resonance-guided focused ultrasound in Parkinson's disease: a phase I study","volume":"37","author":"Meng","year":"2022","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.011_bib60","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.011_bib61","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.011_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00660-20","article-title":"The cell biology of LRRK2 in Parkinson's disease","volume":"41","author":"Usmani","year":"2021","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.011_bib73","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov Disord"},{"issue":"648","key":"10.1016\/j.ncl.2024.12.011_bib75","doi-asserted-by":"crossref","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci Transl Med"},{"issue":"21","key":"10.1016\/j.ncl.2024.12.011_bib79","doi-asserted-by":"crossref","first-page":"14912","DOI":"10.1021\/acs.jmedchem.3c01486","article-title":"Discovery of MK-1468: a potent, kinome-selective, brain-penetrant amidoisoquinoline LRRK2 inhibitor for the potential treatment of Parkinson's disease","volume":"66","author":"Kattar","year":"2023","journal-title":"J\u00a0Med Chem"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.011_bib83","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12017-023-08738-1","article-title":"The ubiquitin proteasome system as a therapeutic area in Parkinson's disease","volume":"25","author":"Suresh","year":"2023","journal-title":"NeuroMolecular Med"},{"issue":"23","key":"10.1016\/j.ncl.2024.12.011_bib85","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1042\/BCJ20210508","article-title":"Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches","volume":"478","author":"Tsefou","year":"2021","journal-title":"Biochem J"},{"issue":"18","key":"10.1016\/j.ncl.2024.12.011_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba1193","article-title":"Intracellular delivery of Parkin rescues neurons from accumulation of damaged mitochondria and pathological \u03b1-synuclein","volume":"6","author":"Chung","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.ncl.2024.12.011_bib88","article-title":"Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models","author":"Hertz","year":"2024","journal-title":"Res Sq"},{"key":"10.1016\/j.ncl.2024.12.011_bib90","article-title":"Retromer stabilization using a pharmacological chaperone protects in an \u03b1-synuclein based mouse model of Parkinson's","author":"Eleuteri","year":"2023","journal-title":"Res Sq"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:18:37Z","timestamp":1762309117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861924001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0733861924001063"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.011","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Medicine in Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}